People Background Check
Find People:

Elliot S Barnathan, Age 69Pittsburgh, PA

Get Report
Known as:
Elliot Dr Barnathan Elliot Stephen Barnathan Elliott S Barnathan Eliott Barnathan Ellio Barnathan Evan Barnathan Stephen Barnathan Elliot
Related to:
Arnold Skolnik 78

Elliot Barnathan Phones & Addresses

Havertown, PA

Philadelphia, PA

1734 Ridgeway Rd, Havertown, PA 19083 (610) 446-2023 (610) 446-6296

1734 Ridgeway Rd, Havertown, PA 19083 (610) 446-6296

Work

Position: Medical Professional

Education

Degree: Graduate or professional degree

Emails

e***[email protected]

Mentions for Elliot S Barnathan

Career records & work history

Medicine Doctors

Elliot Barnathan Photo 1

Elliot Stephen Barnathan, Philadelphia PA

Specialties:
Internal Medicine
Cardiovascular Disease
Cardiology
Work:
Clinical Health Care Associates NJ PC
3400 Spruce St, Philadelphia, PA 19175Clinical Health Care Associates NJ PC
39Th And Market Sts, Philadelphia, PA 19104
Education:
University of Pennsylvania(1981)

License Records

Elliot Stephen Barnathan

Address:
Delaware
Havertown, PA 19083
Licenses:
License #: MD027839E - Active
Category: Medicine
Type: Medical Physician and Surgeon

Elliot Stephen Barnathan

Licenses:
License #: MT008081T - Expired
Category: Medicine
Type: Graduate Medical Trainee

Elliot Barnathan resumes & CV records

Resumes

Elliot Barnathan Photo 6

Executive Director

Location:
Malvern, PA
Industry:
Pharmaceuticals
Work:
Janssen Research and Development, LLC since 2012
Executive Director Johnson&Johnson since 1997
Executive Director J&J Centocor R&D since 1997
Executive Director Johnson & Johnson since 1997
Executive Director Johnson & Johnson/ Centocor Ortho Biotech/ Janssen since 1997
Executive Director Centocor 1997 - Dec 2011
Executive Director American Heart Association 2005 - 2008
President, Souteastern PA Affiliate University of Pennsylvania School or Medicine - Philadelphia, PA 1987 - 1997
Associate Professor of Medicine with tenure
Education:
University of Pennsylvania
BA, Biology University of Pennsylvania School of Medicine
Doctor of Medicine (MD)
Skills:
Clinical Development, Drug Development, Pharmaceutical Industry, Biotechnology, Biopharmaceuticals, Clinical Trials, Immunology, Clinical Research, Life Sciences, Regulatory Submissions, Cardiology, Fda, Medical Devices, Oncology, Lifesciences, Ctms, Biomarkers, Medical Affairs, Gcp, Infectious Diseases, Drug Discovery, Pharmacology, Medical Writing, Translational Medicine, Pharmacokinetics, Ind, Good Clinical Practice, Digital Photography
Interests:
Family
Com Www
Www
Cooking
Com/Barnathanes
Barnathanphotography
Photography
Sports
500Px
Health
Travel
Comwww
Languages:
Spanish
Certifications:
Board Certified, Internal Medicine and Cardiovascular Disease
Elliot Barnathan Photo 7

Executive Director

Location:
1734 Ridgeway Rd, Havertown, PA
Industry:
Pharmaceuticals
Work:
Centocor
Executive Director

Publications & IP owners

Us Patents

Markers And Methods For Assessing And Treating Severe Or Persistant Asthma And Tnf Related Disorders

US Patent:
2010033, Dec 30, 2010
Filed:
Mar 19, 2009
Appl. No.:
12/867910
Inventors:
Chris Huang - Radnor PA, US
Rosemary Watt - Malvern PA, US
Elliot Barnathan - Malvern PA, US
Kim Hung Lo - Wayne PA, US
International Classification:
C40B 30/04
C40B 40/06
US Classification:
506 9, 506 16
Abstract:
A method for assessment of the suitability of and/or effectiveness of a target therapy for a TNF-mediated-related disorder, such as severe or persistent asthma, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes corresponding to contacting the sample with a panel of nucleic acid segments consisting of at least a portion of at least one member from the group consisting of the nucleotide sequences corresponding to at least one of TNFRSF1A SNP rs4149581 (SEQ ID NO:1), TNFRSF1 B SNP rs3766730 (SEQ ID NO:2) or TNFRSFI B SNP rs590977 (SEQ ID NO:3) SNPs which results in a determination that one or more of said SNPs in a sample are in linkage disequilibrium (LD). The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies.

Methods Of Modulating Tissue Growth And Regeneration

US Patent:
5902799, May 11, 1999
Filed:
Aug 5, 1997
Appl. No.:
8/906501
Inventors:
Howard C. Herrmann - Bryn Mawr PA
Elliot Barnathan - Havertown PA
Paul B. Weisz - State College PA
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K31/715;31/735
US Classification:
514 58
Abstract:
Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

Methods Of Inhibiting Restenosis

US Patent:
5637575, Jun 10, 1997
Filed:
Jun 23, 1993
Appl. No.:
8/081493
Inventors:
Howard C. Herrmann - Yardley PA
Elliot Barnathan - Havertown PA
Paul Weisz - Yardley PA
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 3170
C08B 3702
C08B 3716
US Classification:
514 58
Abstract:
Disclosed are compositions and methods effective for inhibiting restenosis. In particular, the present invention provides compositions for inhibiting undesired smooth muscle cell growth or proliferation following angioplasty in mammals, said composition comprising active agents comprising a very water-soluble derivative of cyclodextrin. The invention also provides methods of inhibiting undesired smooth muscle cell growth or proliferation following angioplasty in mammals comprising orally administering to the mammal a growth-inhibiting amount of an active agent comprising a very water-soluble derivative of cyclodextrin.

Immunotargeting Of Plasminogen Activators To The Pulmonary Endothelium

US Patent:
5653979, Aug 5, 1997
Filed:
Mar 30, 1995
Appl. No.:
8/413415
Inventors:
Vladimir R. Muzykantov - Philadelphia PA
Elliot S. Barnathan - Havertown PA
Assignee:
Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 3516
A61K 3542
A61K 3836
A61K 39395
US Classification:
4241781
Abstract:
A multimolecular complex made up of a plasminogen activator conjugated to anti-ACE Mab 9B9 capable of delivering the plasminogen activator to the pulmonary endothelium is provided. Methods of using this complex to selectively deliver the plasminogen activator to the pulmonary endothelium to enhance fibrinolysis in the lungs of an animal are also provided. In addition, a method of prolonging the time a plasminogen activator is present in the circulation of an animal by conjugating the plasminogen activator to anti-ACE Mab 9B9 is also provided.

Compositions And Methods For Modulating Growth Of A Tissue In A Mammal

US Patent:
5874419, Feb 23, 1999
Filed:
Aug 4, 1997
Appl. No.:
8/905612
Inventors:
Howard C. Herrmann - Bryn Mawr PA
Elliot Barnathan - Havertown PA
Paul B. Weisz - State College PA
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 31735
A61K 4702
C08B 3716
US Classification:
514 58
Abstract:
Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

Methods Of Thromboprophylaxis

US Patent:
2022019, Jun 23, 2022
Filed:
Dec 16, 2021
Appl. No.:
17/553340
Inventors:
- Titusville NJ, US
- Berlin, DE
Dagmar Kubitza - Ratingen, DE
Roger M. Mills - Chagrin Falls OH, US
Catherine Vanden Boom - Perkasie PA, US
Elliot Barnathan - Havertown PA, US
Liza Miriam Pina - Fleminnton NJ, US
Assignee:
JANSSEN PHARMACEUTICALS, INC. - Titusville NJ
BAYER PHARMA ATKIENGESELLSCHAFT - Berlin
International Classification:
A61K 31/5377
A61K 9/00
A61P 7/02
Abstract:
Methods of thromboprophylaxis using rivaroxaban is provided for children with congenital heart disease post-Fontan procedure.

Possible Relatives

Elliot H King  Elliot S Kolb  Elliot L Lane  Elliot G Stone  Elliot L Lewis  Elliot A Long  Elliot J Lopez  Elliot P Strong  Elliot J Maldonado  Elliot L Marks 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.